Advertisement

Topics

Akebia Therapeutics to Host Analyst and Investor Day on June 27, 2017

07:00 EDT 20 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that it will ...

Other Sources for this Article

Akebia:
Theresa McNeely, 617-844-6113
SVP, Corporate Communications
and Investor Relations
tmcneely@akebia.com

NEXT ARTICLE

More From BioPortfolio on "Akebia Therapeutics to Host Analyst and Investor Day on June 27, 2017"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Renal disease
Chronic kidney disease (CKD), also known as chronic renal disease, is a progressive loss in renal function over a period of months or years. The symptoms of worsening kidney function are non-specific, and might include feeling generally unwell and experi...

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...